Clinical data | |
---|---|
Age, years | 59.8 (29–83) |
Sex, women | 67 (86%) |
Disease duration, years | 11.9 (3–32) |
Laboratory data | |
No anti-SSA | 24 (31%) |
Anti-SSA alone | 34 (44%) |
Anti-SSA+anti-SSB | 20 (25%) |
Rituximab regimen | |
1 g×2, n (%) | 67 (86%) |
375 mg/m2×4, n (%) | 11 (14%) |
Previous treatments | |
Corticosteroids | 66 (85%) |
Hydroxychloroquine | 44 (56%) |
Methotrexate | 33 (42%) |
Azathioprine | 19 (24%) |
Leflunomide | 8 (10%) |
Intravenous immunoglobulin | 3 (4%) |
Plasmatic exchanges | 3 (4%) |
Concomitant immunosuppressants | |
Corticosteroids | 7 (9%) |
Hydroxychloroquine | 7 (9%) |
Methotrexate | 7 (9%) |
Azathioprine | 1 (1%) |
Mycophenolate mofetil | 1 (1%) |
Cyclophosphamide | 1 (1%) |
Results are expressed as n (%).
AIR, AutoImmune and Rituximab registry; pSS, primary Sjögren's syndrome.